Latest stories on CATX
Perspective Therapeutics, Inc. (CATX) files 8-K
SEC 8-K50 · neutralgeneral
Perspective Therapeutics: 'Strong Buy' On Bamzireotide Navoxetan Reinforced Data And Phase 3 Plans
Seeking Alpha73 · bullishanalyst
BMO initiates Perspective Therapeutics stock at Outperform, $11 target
Investing.com Analyst Ratings61 · neutralanalyst
BMO Capital starts Perspective at Outperform, cites pipeline opportunities
The Fly63 · neutralanalyst
Perspective Therapeutics initiated with an Outperform at BMO Capital
The Fly61 · neutralanalyst
Perspective Therapeutics Price Target Lowered To 14 From 16 At Piper Sandler
The Fly34 · bearishanalyst
Perspective Therapeutics GAAP EPS of -$0.22 beats by $0.04, revenue of $0.08M misses by $0.01M
Seeking Alpha56 · neutralearnings
Perspective Therapeutics, Inc. (CATX) files 8-K
SEC 8-K50 · neutralgeneral
Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2026 Results
StockTitan56 · neutralearnings
Perspective Therapeutics, Inc. (CATX) files 8-K
SEC 8-K50 · neutralgeneral
Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Results
Business Insider50 · neutralgeneral
BTIG reiterates Perspective Therapeutics stock rating on manufacturing edge
Investing.com Analyst Ratings56 · neutralanalyst
Perspective Therapeutics (CATX) Reports Encouraging Early Data Across Multiple Radiopharmaceutical Trials
Yahoo Top63 · neutralproduct/pr
Perspective Therapeutics, Inc. (CATX) files 8-K
SEC 8-K50 · neutralgeneral
Perspective Therapeutics Highlights Progress in Alpha Radiopharmaceutical Pipeline
TipRanks65 · bullishproduct/pr
Perspective Therapeutics Showcases Strong Interim Radiopharma Data
TipRanks67 · bullishproduct/pr